Supplementary File

Contents

Supplementary Table S1: Summary of the included studies:

Study ID	Country	Phase	Total participants	Route	Dose	Escalation	Comparator	Inclusion criteria	Exclusion criteria	Primary endpoints
Flack 2025	214 clinical sites across multiple countries	Phase 3	796	Oral	1–2 mg once daily	None	Placebo	Adults ≥18 years with uncontrolled HTN on 2 drugs or resistant HTN on ≥3 (including a diuretic); seated SBP 140–<170 mmHg at screening and ≥135 mmHg after placebo run-in.	Secondary hypertension, recent major CV events, severe renal impairment, hyperkalemia, or use of MRAs/potassium-sparing diuretics.	12 weeks
Freeman 2022	The UK.	Phase 2	275	Oral	0.5, 1, 2 mg once daily	None	Placebo	Adults ≥18 years on stable ≥3 antihypertensives (including a diuretic), with seated mean BP ≥130/80 mmHg (average of 3 automated office readings).	Mean seated SBP ≥180 mmHg or DBP ≥110 mmHg, eGFR <45 mL/min/1.73m², uncontrolled diabetes.	12 weeks
Dwyer 2025	The US	Phase 2	195	Oral	0.5, 1, 2,4 mg once daily	at week 3: 0.5 escalated to 1 mg/; 2 escalated to 4 mg	Placebo	Participants aged >18 years with an eGFR of 25–75 ml/min per 1.73 m2 at screening, a urine albumin-creatinine ratio (UACR) of > 100 mg/g, and a mean seated office systolic BP between 140 and 180 mm Hg without diabetes or between 130 and 180 mm Hg with type 2 diabetes.	Type 1 diabetes, HbA1C > 10.5% at screening, or were concomitantly treated with MRAs or potassium-sparing diuretics.	26 weeks

Supplementary table S2: Protocols registered

NCT Number	Study Name / Program	Status (as of May 2026)	Study Population	Publication & Results Status	Link
NCT06034743	BaxHTN (Phase III)	Completed	Uncontrolled or treatment-resistant hypertension (on 2+ medications).	Published: NEJM (Oct 2025). Met primary endpoint.	https://clinicaltrials.gov/study/NCT06034743?cond=NCT06034743&viewType=Card&rank=1
NCT06168409	Bax24 (Phase III)	Completed	Treatment-resistant hypertension (focus on 24-hr ambulatory BP)	Published: The Lancet / Presented at AHA (2025).	https://clinicaltrials.gov/study/NCT06168409?cond=NCT06168409&viewType=Card&rank=1
NCT06344104	BaxAsia (Phase III)	Completed	Uncontrolled or resistant hypertension primarily in Asian populations.	No Results published	https://clinicaltrials.gov/study/NCT06344104?cond=NCT06344104&viewType=Card&rank=1
NCT04519658	BrigHTN (Phase II)	Completed	Patients with treatment-resistant hypertension (BP ≥130/80 on 3+ meds).	Published: NEJM (Feb 2023). Showed dose-dependent BP reduction.	https://clinicaltrials.gov/study/NCT04519658?cond=NCT04519658&viewType=Card&rank=1
NCT05137002	HALO (Phase II)	Completed	Uncontrolled hypertension (on 1–2 medications at max doses).	Published: Presented at ACC 2023 and reported in AJMC. The trial did not meet its primary endpoint because of a high placebo response.	https://clinicaltrials.gov/study/NCT05137002?cond=NCT05137002&viewType=Card&rank=1
NCT06268873	BaxDuo-Pacific (P III)	Active not recruiting	Chronic Kidney Disease (CKD) and high blood pressure.	Published: JASN (2025); significant reduction in systolic BP observed with baxdrostat in CKD and uncontrolled hypertension.	https://clinicaltrials.gov/study/NCT06268873?cond=NCT06268873&viewType=Card&rank=1

Supplementary Figure S1: Change in Serum Aldosterone



Supplementary Figure S2: Change in plasma renin activity



Supplementary Figure S3: Baujat plot for plasma renin activity



Supplementary Figure S4: Change in eGFR



Supplementary Figure S5: Baujat plot for eGFR



Supplementary Figure S6: Change in serum potassium



Supplementary Figure S7: Baujat plot for serum potassium



Supplementary Figure S8: Adverse events, any serious adverse event, death, hyperkalemia, symptomatic hypotension, and hyponatremia